GoodRx, Novo Nordisk rise on plans to offer Ozempic at $499 per month

GoodRx Holdings

18/08/2025 14:59

** Shares of telehealth firm GoodRx GDRX.O rise 29.5% to $4.83 in early trade

** Novo Nordisk NOVOb.CO, NVO.N says it is partnering with GDRX to offer both Wegovy and Ozempic for $499 per month

** NVO says it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 diabetes patients in the United States

** U.S.-listed shares of the Danish drugmaker up 5.8% at $54.85

** Separately, U.S. FDA on Friday granted accelerated approval for NVO's weight-loss drug Wegovy to treat a serious liver condition called metabolic dysfunction-associated steatohepatitis

** Including session's move, GDRX up 2.7% and NVO down 36.3% YTD

 (Reporting by Puyaan Singh)

 ((Puyaan.Singh@thomsonreuters.com;))